Salarius Pharmaceuticals Inc. (SLRX)

$1.41

-0.04

(-2.76%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $1.33
    $1.43
    $1.41
    downward going graph

    5.67%

    Downside

    Day's Volatility :6.91%

    Upside

    1.31%

    downward going graph
  • $1.35
    $7.44
    $1.41
    downward going graph

    4.26%

    Downside

    52 Weeks Volatility :81.85%

    Upside

    81.05%

    downward going graph

Returns

PeriodSalarius Pharmaceuticals Inc.Index (Russel 2000)
3 Months
-36.26%
0.0%
6 Months
-64.29%
0.0%
1 Year
-71.68%
0.0%
3 Years
-99.28%
-20.2%

Highlights

Market Capitalization
2.0M
Book Value
$3.71
Earnings Per Share (EPS)
-8.73
PEG Ratio
0.0
Wall Street Target Price
26.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-53.99%
Return On Equity TTM
-119.83%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-15.8M
EBITDA
-6.7M
Diluted Eps TTM
-8.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.04
EPS Estimate Next Year
-9.17
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
-2.4

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Salarius Pharmaceuticals Inc.(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 1743.97%

Current $1.41
Target $26.00

Technicals Summary

Sell

Neutral

Buy

Salarius Pharmaceuticals Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc.
-3.97%
-64.29%
-71.68%
-99.28%
-99.87%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-13.97%
8.28%
24.49%
82.67%
258.6%
Novo Nordisk A/s
Novo Nordisk A/s
-14.46%
-7.16%
29.25%
137.43%
348.48%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.47%
77.93%
59.32%
38.21%
249.95%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
12.26%
28.5%
155.67%
163.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc.
NA
NA
0.0
-4.04
-1.2
-0.54
NA
3.71
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.42
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.7
38.7
1.75
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc.
Sell
$2.0M
-99.87%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.7B
258.6%
27.55
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$518.0B
348.48%
38.7
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.9B
249.95%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.3B
163.05%
32.84
-4.74%

Insights on Salarius Pharmaceuticals Inc.

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.3% return, outperforming this stock by 131.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.2% return, outperforming this stock by 137.5%

Institutional Holdings

  • Armistice Capital, LLC

    1.58%

  • Tower Research Capital LLC

    0.22%

  • UBS Group AG

    0.01%

Company Information

salarius is an oncology based biotechnology company developing targeted treatments for patients who need them the most.

Organization
Salarius Pharmaceuticals Inc.
Employees
2
CEO
Mr. David J. Arthur M.B.A.
Industry
Health Technology

Discover More

FAQs